Theralase Technologies Inc. (TLTFF)
OTCMKTS
· Delayed Price · Currency is USD
0.1200
-0.0093 (-7.16%)
May 21, 2025, 4:00 PM EDT
Theralase Technologies Revenue
In the year 2024, Theralase Technologies had annual revenue of 1.03M CAD, down -3.45%. Theralase Technologies had revenue of 410.45K in the quarter ending December 31, 2024, with 12.88% growth.
Revenue
1.03M CAD
Revenue Growth
-3.45%
P/S Ratio
41.34
Revenue / Employee
51.67K CAD
Employees
20
Market Cap
29.69M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.03M | -36.88K | -3.45% |
Dec 31, 2023 | 1.07M | -68.26K | -6.00% |
Dec 31, 2022 | 1.14M | 357.93K | 45.85% |
Dec 31, 2021 | 780.64K | -148.48K | -15.98% |
Dec 31, 2020 | 929.12K | -34.93K | -3.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
Theralase Technologies News
- 2 days ago - Theralase Provides Corporate Update - Newsfile Corp
- 17 days ago - Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association - Newsfile Corp
- 24 days ago - Theralase Discovers New Mechanism of Action of Lead Drug - Newsfile Corp
- 5 weeks ago - Theralase(R) Closes Non-Brokered Private Placement - Newsfile Corp
- 6 weeks ago - Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments - Newsfile Corp
- 6 weeks ago - Ruvidar Demonstrates 7 Year Complete Response - Newsfile Corp
- 2 months ago - Ruvidar Effective in the Treatment of Herpes - Newsfile Corp
- 2 months ago - Theralase Technologies Inc. (TLTFF) Q4 2024 Earnings Call Transcript - Seeking Alpha